Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia.
Sci Rep
; 11(1): 15052, 2021 07 23.
Article
in En
| MEDLINE
| ID: mdl-34302010
ABSTRACT
Prostate-specific antigen (PSA) screening for prostate cancer (PCa) is limited by the lack of specificity but is further complicated in the benign prostatic hyperplasia (BPH) population which also exhibit elevated PSA, representing a clear unmet need to distinguish BPH from PCa. Herein, we evaluated the utility of FLNA IP-MRM, age, and prostate volume to stratify men with BPH from those with PCa. Diagnostic performance of the biomarker panel was better than PSA alone in discriminating patients with negative biopsy from those with PCa, as well as those who have had multiple prior biopsies (AUC 0.75 and 0.87 compared to AUC of PSA alone 0.55 and 0.57 for patients who have had single compared to multiple negative biopsies, respectively). Of interest, in patients with PCa, the panel demonstrated improved performance than PSA alone in those with Gleason scores of 5-7 (AUC 0.76 vs. 0.56) and Gleason scores of 8-10 (AUC 0.74 vs. 0.47). With Gleason scores (8-10), the negative predictive value of the panel is 0.97, indicating potential to limit false negatives in aggressive cancers. Together, these data demonstrate the ability of the biomarker panel to perform better than PSA alone in men with BPH, thus preventing unnecessary biopsies.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prostatic Hyperplasia
/
Prostatic Neoplasms
/
Biomarkers, Tumor
/
Diagnosis, Differential
Type of study:
Diagnostic_studies
/
Prognostic_studies
Limits:
Aged
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Sci Rep
Year:
2021
Document type:
Article
Affiliation country:
United States